Table 2.
Review of current literature
| Study | NACH/N (n) | Gender (M/F) | Age (mo) | CH regimen | CH morbidity | PR CH | Complete resection | Postoperative events | OS | DFS |
| Pritchard et al[8], 2000 SIOPEL-1 | 138/154 | 97/ 57 | 16.5 | PLADO (cis+dox) | 2% death 6% myelotoxicity < 2% others | 82% | 92% | 5 deaths 8% infections 3% bleeding 9% others | 75% | 66% |
| Katzenstein et al[18], 2002 | 33/33 | 21/12 | 22 | Car-vin-5FU | 60% myelotoxicity | 82% | 58% | - | 57% | 48% |
| Perilongo et al[14], 2004 SIOPEL-2 | 135/135 | 81/54 | 16-25 | Cis Car-dox-cis | Neutropenia 43%-81% Infections 40%-76% Transfusion 19%-76% | 90% (SR HB) 78% (HR HB) 90% (SR-HR) | 97% (SR HB) 67% (HR HB) 100% (SR-HR) | - | 91% (SR HB) 53% (HR HB) 86% (SR-HR) | 89% (SR HB) 48% (HR HB) 89% (SR-HR) |
| Towu et al[16], 2004 | 54/56 | 34/22 | 12 | 22 PLADO 14 SIOPEL-2 17 SIOPEL-3 | - | 92% | 74% | 1 death 22% (bile leakage, collections, others) | 75% | - |
| Zsíros et al[15], 2010 SIOPEL-3 | 150/151 | 90/61 | 21 | Cis/car-dox | 1 death 76% neutropenia 51% infections 33% renal toxicity | 78.70% | 76.20% | 4 deaths | 69%1 | 65% |
| Lautz et al[19], 2010 | 14/14 | 7/7 | 8 | Cis-vin-5FU Others | - | 61% | 85% | 1 Iscq cholangio 1 portal thrombosis | 88% | 77% |
| Hishiki et al[17], 2011 | 185/212 | 132/80 | 17 | Cis-pir Iof-car-pir-eto | 90% neutropenia 10% infections < 10% others | 65% | 63% | - | 81% | 62.4% |
1
3-year overall survival. NACH: Number of patients with neoadjuvant chemotherapy; N: Total number of patients; CH: Chemotherapy; PR: Partial response; OS: 5-year overall survival; DFS: Disease-free survival; cis: Cisplatin; dox: Doxorubicin; car: Carboplatin; pir: Pirarubicin; iof: Ifosfamide; eto: Etoposide; vin: Vincristine; 5FU: 5-fluorouracil; SR HB: Standard risk hepatoblastoma; HR HB: High risk hepatoblastoma; SR-HR: Standard risk hepatoblastoma treated as high risk hepatoblastoma.